Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Aug 02, 2021	RYAN ARTHUR F Director Trans History: 524	Director	Form 4	Open market or private sale of non-derivative or derivative security	28	$578.67	23,433
Nov 02, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 617	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	268	$578.73	545,248
May 28, 2020	GOLDSTEIN JOSEPH L Director Trans History: 381	Director	Form 4	Open market or private sale of non-derivative or derivative security	1,000	$578.94	6,643
Aug 02, 2021	RYAN ARTHUR F Director Trans History: 524	Director	Form 4	Open market or private sale of non-derivative or derivative security	39	$579.35	23,394
Aug 13, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	4,667	$579.35	21,154
Aug 13, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	2,749	$579.35	18,405
Aug 13, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	4,521	$579.35	28,509
Aug 13, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	5,210	$579.35	23,299
Aug 13, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	2,065	$579.35	44,234
Aug 13, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,795	$579.35	33,439

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media